ATE350041T1 - Pharmaceutishe zusammensetzung für die hormonersatztherapie - Google Patents

Pharmaceutishe zusammensetzung für die hormonersatztherapie

Info

Publication number
ATE350041T1
ATE350041T1 AT02738951T AT02738951T ATE350041T1 AT E350041 T1 ATE350041 T1 AT E350041T1 AT 02738951 T AT02738951 T AT 02738951T AT 02738951 T AT02738951 T AT 02738951T AT E350041 T1 ATE350041 T1 AT E350041T1
Authority
AT
Austria
Prior art keywords
formula
hormone replacement
replacement therapy
group
pharmaceutical composition
Prior art date
Application number
AT02738951T
Other languages
English (en)
Inventor
Christian Franz Holinka
Bennink Herman Jan Ti Coelingh
Evert Johannes Bunschoten
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01201896A external-priority patent/EP1260225A1/de
Priority claimed from EP01201945A external-priority patent/EP1293210B1/de
Priority claimed from EP01203305A external-priority patent/EP1287817A1/de
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE350041T1 publication Critical patent/ATE350041T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT02738951T 2001-05-18 2002-05-17 Pharmaceutishe zusammensetzung für die hormonersatztherapie ATE350041T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP01201896A EP1260225A1 (de) 2001-05-18 2001-05-18 Pharmazeutische Zusammensetzung für die Hormonersatztherapie
EP01201947 2001-05-23
EP01201946 2001-05-23
EP01201945A EP1293210B1 (de) 2001-05-23 2001-05-23 Zubereitungen für die hormonale Kontrazeption
EP01203305A EP1287817A1 (de) 2001-08-31 2001-08-31 Verfahren und intravaginales Arzneiverabreichungsvorrichtung zur Behandlung von uterinem Myom
EP01204377 2001-11-15
EP02075695 2002-02-21

Publications (1)

Publication Number Publication Date
ATE350041T1 true ATE350041T1 (de) 2007-01-15

Family

ID=27561854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02738951T ATE350041T1 (de) 2001-05-18 2002-05-17 Pharmaceutishe zusammensetzung für die hormonersatztherapie

Country Status (10)

Country Link
US (1) US8048869B2 (de)
EP (1) EP1390040B1 (de)
AT (1) ATE350041T1 (de)
CA (1) CA2447178C (de)
CY (1) CY1106457T1 (de)
DE (1) DE60217324T2 (de)
DK (1) DK1390040T3 (de)
ES (1) ES2278924T3 (de)
PT (1) PT1390040E (de)
WO (1) WO2002094276A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US20050096283A1 (en) * 2001-12-14 2005-05-05 The Regents Of University Of California Methods of inhibiting fertility
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
AU2003279624A1 (en) 2002-11-08 2004-06-07 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
JP2006526025A (ja) * 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
EP1756139A4 (de) * 2004-03-12 2009-07-29 Entremed Inc Antiangiogene mittel
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
US20060116360A1 (en) * 2004-11-29 2006-06-01 Fogler William E Method of administering anti-angiogenic agents and a method of treating disease using same
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20100048523A1 (en) * 2006-04-07 2010-02-25 Bachman Kurtis E Compounds, Compositions and Methods for Treating Hormone-Dependent Maladies
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
WO2009075838A2 (en) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Treatment of menorrhagia with aromatase inhibitor
WO2012164096A1 (en) 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
BR112013030833B1 (pt) 2011-06-01 2019-09-03 Estetra S A processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol
EP2383279A1 (de) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Herstellungsverfahren für Esterol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3046928B1 (de) 2013-09-18 2017-02-08 Crystal Pharma, S.A.U. Verfahren zur herstellung von estetrol
HUE035848T2 (en) * 2013-12-12 2018-05-28 Donesta Bioscience B V Solid dispensing unit containing an estetrol compound in the mouth
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016203044A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
NZ737945A (en) * 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CR20200486A (es) 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336433A1 (de) * 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) * 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) * 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) * 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
ES2247710T3 (es) 1997-06-20 2006-03-01 Akzo Nobel N.V. Antagonista de gonadotropina.
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
JP2003527310A (ja) 1999-04-16 2003-09-16 イエナフアルム ゲーエムベーハー ウント ツェーオー． カーゲー エストロゲンを局部的に皮内投与するための医薬品組成物または化粧品組成物
WO2000073416A1 (en) 1999-05-28 2000-12-07 University Of Cincinnati Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US7371385B2 (en) 2000-05-12 2008-05-13 Oregon Health & Science University Method of treating immune pathologies with low dose estrogen
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (de) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie

Also Published As

Publication number Publication date
CA2447178A1 (en) 2002-11-28
EP1390040A1 (de) 2004-02-25
WO2002094276A1 (en) 2002-11-28
PT1390040E (pt) 2007-04-30
DE60217324D1 (de) 2007-02-15
EP1390040B1 (de) 2007-01-03
CY1106457T1 (el) 2011-10-12
DK1390040T3 (da) 2007-04-23
US8048869B2 (en) 2011-11-01
DE60217324T2 (de) 2007-04-26
ES2278924T3 (es) 2007-08-16
US20040198671A1 (en) 2004-10-07
CA2447178C (en) 2010-06-08

Similar Documents

Publication Publication Date Title
DE60217324D1 (de) Pharmaceutishe zusammensetzung für die hormonersatztherapie
DE60216630D1 (de) Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
DK1390039T3 (da) Anvendelse af östrogenforbindelser til forögelse af kvinders libido
EP1028715A4 (de) Dosiszusammensetzung zur nasalen verabreichung und verfahren zu deren verwendung
GEP20012530B (en) Neuroactive Steroids of the Androstane and Pregnane Series
GR3031448T3 (en) Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
AU3805195A (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
DE59901020D1 (de) 14,15-cyclopropanosteroide der 19-norandrostan-reihe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate
IL164974A0 (en) Novel compounds and their use
ATE534656T1 (de) Neue oligosaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
NZ312303A (en) Novel nor-pregnanes for inducing hypothalamic effects
SI1511496T1 (sl) Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
ZA9811240B (en) New aryl-substituted pyridylalkane alkene and alkine carboxamides
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
ATE356637T1 (de) Supramolekulare komplexe enthaltende arzneimittel
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
ME00624B (me) Nova primjena docetaksela za liječenje hepatoma
MY117307A (en) New harmone medicaments and their use for correction of oestrogen deficiencies.
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
KR960703593A (ko) (R)-암로디핀에 의한 평활근 세포 이동의 억제 (Inhibition of Smooth Muscle Cell Migration by (R)-Amlodipine)
DE50110892D1 (de) 17alpha-fluoralkylsteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
PT1603532E (pt) Sistema de entrega subcutâneo que compreende um inibidor de acetilcolinesterase
KR930702985A (ko) 식도암의 치료
HUP9801846A2 (hu) 17-(Difluor-metilén)-ösztratriének, alkalmazásuk, az ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására
DE59900775D1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390040

Country of ref document: EP